Search company, investor...

Mobius Therapeutics


Loan | Alive

Total Raised


Last Raised

$250K | 3 yrs ago

About Mobius Therapeutics

Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization; the pterygium and refractive indications are awaiting approval by the Food and Drug Administration.

Headquarters Location

4041 Forest Park Avenue

St. Louis, Missouri, 63108,

United States


Missing: Mobius Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Mobius Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Mobius Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Mobius Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Mobius Therapeutics Patents

Mobius Therapeutics has filed 12 patents.

The 3 most popular patent topics include:

  • Dosage forms
  • Drug delivery devices
  • Eye surgery
patents chart

Application Date

Grant Date


Related Topics




Valves, Plumbing, Life sciences industry, Plumbing valves, Pharmaceutical industry


Application Date


Grant Date



Related Topics

Valves, Plumbing, Life sciences industry, Plumbing valves, Pharmaceutical industry



Latest Mobius Therapeutics News

Mobius Therapeutics Granted New US Patent for Injected Ophthalmic Mitomycin-C

Jan 4, 2023

Mobius Therapeutics has been issued US Patent #11,540,977, "Injection Apparatus and Method of Use," protecting future applications of Mitosol, Mobius’ flagship product, particularly versus compounded, unapproved copies of Mitosol. “This is an important addition to Mobius’ IP portfolio,” said Ed Timm, CEO of Mobius Therapeutics. “As the gold standard for ophthalmic mitomycin, this patent acknowledges the novelty and merits inherent to Mitosol. It protects the apparatus itself, its unique ability to protect healthcare workers, and its ultimate flexibility in accommodating all clinical needs.” Mitosol is the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication. With room temperature storage, shelf life of up to 24 months, and USP <800> compliance, Mitosol offers flexibility to providers, as its “shelf-ready” status permits on-demand utility. “Ophthalmic surgeons are smart and resourceful physicians, relentlessly advancing clinical excellence with improved clinical technique,” Mr. Timm said. “Mobius shares this passion. Franchise protection provides the resources required to respond with products to meet and exceed these demanding needs, now and into the future. In the end, everyone wins: the patient, the provider, and the American healthcare system.”

Mobius Therapeutics Frequently Asked Questions (FAQ)

  • Where is Mobius Therapeutics's headquarters?

    Mobius Therapeutics's headquarters is located at 4041 Forest Park Avenue, St. Louis.

  • What is Mobius Therapeutics's latest funding round?

    Mobius Therapeutics's latest funding round is Loan.

  • How much did Mobius Therapeutics raise?

    Mobius Therapeutics raised a total of $7.86M.

  • Who are the investors of Mobius Therapeutics?

    Investors of Mobius Therapeutics include Paycheck Protection Program, Cultivation Capital, Qualifying Therapeutic Discovery Project and St. Louis Enterprise Center West County.

  • Who are Mobius Therapeutics's competitors?

    Competitors of Mobius Therapeutics include Intrinsic Therapeutics, iTind, PulmonX, Cagenix, AirXpanders and 13 more.

Compare Mobius Therapeutics to Competitors

NDO Surgical

Medical devices for the treatment of severe gastrointestinal disorders

Vitreo Retinal Technologies

Vitreo Retinal Technologies, Inc. is developing therapeutics for the treatment of serious ocular diseases.

Perfuzia Medical

Perfuzia Medical is developing the next generation of medical devices for the treatment of chronic wounds.


Portaero, in stealth mode, is a medical devices firm, developing a device for the treatment of COPD (Chronic obstructive pulmonary disease).

SetPoint Medical Logo
SetPoint Medical

SetPoint Medical develops a bioelectronic medicine platform using a small implanted device that activates the body's natural inflammatory reflex and produces a systemic anti-inflammatory effect. It aims to treat patients with chronic autoimmune diseases and provides a treatment alternative for rheumatoid arthritis, inflammatory bowel disease, and other chronic autoimmune conditions. The company was founded in 2006 and is based in Santa Clarita, California.


C2C is a medical device company developing a portfolio of medical devices.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.